Sustainability Report 2012 Lek d.d.

3 Company Profile 1. Company Profile 1 Disclosure GRI 2.8, GRI Indicator EC1, GRI Indicator LA1 2 GRI Indicator EC1 3 GRI Indicator EC4 1.1 Key Data for 2012 1.1.1 Operations in 2012 Table 1: Key figures for 2012 1 Indicator Unit 31. 12. 2012 31. 12. 2011 Index 2012/2011 * Due to extremely big differences in the weight of various types of products, and due to the manufacturing structure being adjusted to the changed demand, the data is difficult to compare. We therefore believe that the comparison of production outputs is irrelevant. Differences in product weight should also be taken into account when reading data on the efficiency per tonne of product. Example: the weight of similar biologicals is low compared to certain self-medication drugs, yet their manufacture requires larger quantities of water and energy resources, and their financial value is higher as well. ** The change in the value over that reported for 2011 results from adjustments made to the data on production output and use of raw materials. The changes occurred due to an improved methodology for collecting data on production output for various finished pharmaceuticals and mass flows of raw materials at the Ljubljana site, the improvement being made on the basis of additional information obtained. Number of employees 2,780 2,571 108 - Ljubljana site 1,713 1,557 110 - Menge‰ site 655 629 104 - Lendava site 245 218 112 - Prevalje site 167 167 100 Production output* 000 tonnes 5.94 5.22** 114 Net sales revenues in EUR m 660.435 623.084 106 Liabilities in EUR m 869.540 873.378 99.6 Equity in EUR m 505.451 499.521 101 Economic performance 2 In 2012, Lek d.d. realized net sales revenues to the amount of EUR 660.435 million, a 6% increase over the year 2011, In foreign markets, they increased by 8%, whereas in the domestic market, they dropped by 8%. Direct Economic Value Generated amounted to EUR 680 million. Of this, Economic Value Distributed totalled EUR 629 million (92.5%), and Economic Value Retained EUR 51 million (7.5%). Within Economic Value Distributed, Operating Costs amounted to EUR 420 million (67%), Employee Costs amounted to EUR 134 million (21%), Payments to Provi- ders of Capital reached EUR 70 million (11%), and Payments to Government totalled EUR 5 million (1% of Economic Value Distributed). Due to increased volume of investment in research activity, the related tax relief doubled against the year before, amounting to EUR 23.811 million. For investments, income tax amounted to EUR 19.44 mil- lion. We also received public subsidies amounting to EUR 263,000. 3 Graph 1: Structure of Economic Value Distributed 1% 21% 67% 11% Operating Costs 67% Employee Costs 21% Payments to Providers of Capital 11% Payments to Government 1%